Monotherapy with lopinavir/ritonavir

Bibliography

• FABIANI M, ACCORSI S, ALENI R et al.: Stimating HIV prevalence and the impact of HIV/AIDS on a Ugandan hospital by combining serosurvey data and hospital discharge records. J. Acquir. Immune Defic. Syndr. (2003) 34(1):62-66.
   PubMed Web of Science ®Google Scholar
• LEWIS DK, CALLAGHAN M, PHIRI K et al.: Prevalence and indicators of HIV and AIDS among adults admitted to medical and surgical wards in Blantyre, Malawi. Trans. R. Soc. Trop. Med. Hyg. (2003) 97(1):91-96.
   PubMed Web of Science ®Google Scholar
• EDGINTON ME, WONG ML, PHOFA R et al.: Tuberculosis at Chris Hani Baragwanath Hospital: numbers of patients diagnosed and outcomes of referrals to district clinics. Int. J. Tuberc. Lung Dis. (2005) 9(4):398-402.
   PubMed Web of Science ®Google Scholar
• PALELLA FJ, DELANEY KM, MOORMAN AC et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. (1998) 338:853-860.
   PubMed Web of Science ®Google Scholar
• HOFER CB, SCHECHTER M; HARRISON LH: Effectiveness of antiretroviral therapy among patients who attend public HIV clinics in Rio de Janeiro, Brazil. J. Acquir. Immune Defic. Syndr. (2004) 36:967-971.
   PubMed Web of Science ®Google Scholar
• TUBOI SH, HARRISON LH, SPRINZ E et al.: Predictors of virological failure in HIV-1 infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. J. Acquir. Immune Defic. Syndr. (2005) 40:324-328.
   PubMed Web of Science ®Google Scholar
• BRAITSTEIN P, BRINKHOF MWG, DABIS F et al.: Mortality of HIV-1-infected patients during the first year of potent antiretroviral therapy: comparative analysis of databases from low and high-income countries. Lancet (2006) 367:817-824.
   PubMed Web of Science ®Google Scholar
• GALVÃO J: Access to antiretroviral drugs in Brazil. Lancet (2002) 360:1862-1865.
   PubMed Web of Science ®Google Scholar
• LUCAS GM, CHAISSON RE, MOORE RD: Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann. Int. Med. (1999) 131(2):81-87.
   PubMed Web of Science ®Google Scholar
• CARR A, SAMARAS K, THORISDOUR A et al.: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet (1999) 353:2093-2099.
   PubMed Web of Science ®Google Scholar
• CARR A, MILLER J, LAW M et al.: A syndrome of lipoatrophy, lactic academia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS (2000) 14:F25-F32.
   PubMed Web of Science ®Google Scholar
• CHENE G, ANGELINE E, COTTE L et al.: Role of long term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin. Infect. Dis. (2002) 34:649-657.
   PubMed Web of Science ®Google Scholar
• HAVLIR DV, MARSCHNER IC, HIRSCH MS et al.: Maintenance antiretroviral therapies in HIV-infected patients with undetectable plasma HIV RNA after triple drug therapy. N. Engl. J. Med. (1998) 339:1261-1268.
   PubMed Web of Science ®Google Scholar
• MURPHY RL, GULLICH RM, DEGRUTTOLA V et al.: Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. J. Infect. Dis. (1999) 179:808-816.
   PubMed Web of Science ®Google Scholar
• HAVLIR DV, HELLMANN NS, PETROPOULOS CJ et al.: Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA (2000) 283(2):229-234.
   PubMed Web of Science ®Google Scholar
• GISOLF EH, JURRIAANS S, PELGROM J et al.: The effect of treatment intensification in HIV infection: a study comparing treatment with ritonavir/saquinavir with ritonavir/saquinavir/stavudine (Prometheus). AIDS (2000) 14:405-413.
   PubMed Web of Science ®Google Scholar
• ARRIBAS J, PULIDO F, DELGADO R et al.: Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48- week results of a randomized, controlled, open label, proof-of-concept pilot clinical trial (OK Study). J. Acquir. Immune Defic. Syndr. (2005) 40(3):280-287.
   PubMed Web of Science ®Google Scholar
• ARRIBAS J, PULIDO F, DELGADO R et al.: Lopinavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: forty eight week results of a randomized, controlled, open label, clinical trial (OK04 Study). Program and abstracts of the XVI International AIDS Conference, Toronto, Canada (13 – 18 August 2006):MOPE0060 (Abstract).
   Google Scholar
• CAMERON W, DA SILVA B, ARRIBAS J et al.: A two-year randomized controlled clinical trial in antiretroviral-naive subjects using lopinavir/ritonavir (LPV/r) monotherapy after initial induction treatment compared to an efavirenz (EFV) 3-drug regimen (study M03-613). Program and abstracts of the XVI International AIDS Conference, Toronto, Canada (13 – 18 August 2006):THLB0201 (Abstract).
   Google Scholar
• NUNES EP, OLIVEIRA MS, ALMEIDA MMTB et al.: 48-week efficacy and safety results of simplification to single agent lopinavir/ritonavir (LPV/r) regimen in patients suppressed below 80 copies/ml on HAART – the KalMo study. Program and abstracts of the XVI International AIDS Conference, Toronto, Canada (13 – 18 August 2006):TUAB0103 (Abstract).
   Google Scholar
• SWINDELLS S, DIRIENZO AG, WILKIN T et al.: Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA (2006) 296:806-814.
   PubMed Web of Science ®Google Scholar
• VERNAZZA P, DANEEL S, SCHIFFER V et al.: Swiss HIV Cohort: viral suppression in CSF and genital tract in ritonavir-boosted ‘atazanavir only’ maintenance therapy (ATARITMO-Study). Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil (24 – 27 July 2005):WeOa0204 (Abstract).
   Google Scholar
• KARLSTRÖM O, JOSEPHSON F, SÖNNERBORG A: Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J. Acquir. Immune Defic. Syndr. (2007) 44(4):417-422.
   PubMed Web of Science ®Google Scholar
• QAZI NA; MORLESE JF; POZNIAK AL: Lopinavir/ritonavir (ABT-378/r). Expert Opin. Pharmacother. (2002) 3(3):315-327.
   PubMedGoogle Scholar
• HICKS C, DA SILVA B, KING M et al.: Extensive resistance testing during 5 years of lopinavir/ritonavir treatment in antiretroviral-naïve HIV-infected patients: results from study 720. Program and abstracts of the XV International AIDS Conference, Bangkok, Thailand (11 – 16 July 2004):WeOrB1291 (Abstract).
   Google Scholar
• VOIGT E, WASMUTH JC, VOGEL M et al.: Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week results. Infection (2004) 32(2):82-88.
   PubMed Web of Science ®Google Scholar
• MURPHY R, DA SILVA B, MCMILLAN F et al.: Seven year follow-up of a lopinavir/ritonavir (LPV/r)-based regimen in antiretroviral (ARV)-naive subjects. 10th European AIDS Conference, Dublin, Ireland (17 – 20 November 2005):PE7.9/3 (Abstract).
   Google Scholar
• PIERONE G, MIERAS J, KANTOR C et al.: Initial clinical experience with Kaletra. (LPV/r) monotherapy in HIV infection. Frontiers in Drug Development for Antiretroviral Therapies (HIV DART 2002), Naples, USA (13 – 18 December 2002):076 (Poster).
   Google Scholar
• GATHE JC, WASHINGTON M, MAYBERRY C et al.: Pilot study of the safety and efficacy of lopinavir/ritonavir (LPV/r) as single agent therapy in HIV-1 ARV naïve patients. IMANI I. XV International AIDS Conference, Bangkok, Thailand (11 – 16 July 2004):MoOr B1057 (Abstract).
   Google Scholar
• DELFRAISSY J-F, FLANDRE P, DELAUGERRE C et al.: MONARK trial (MONotherapy AntiRetroviral Kaletra): 48-week analysis of lopinavir/ritonavir (LPV/r) monotherapy compared to LPV/r + zidovudine/lamivudine (AZT/3TC) in antiretroviral-naive patients. Program and abstracts of the XVI International AIDS Conference, Toronto, Canada (13 – 18 August 2006):THLB0202 (Abstract).
   Google Scholar
• CAMERON DW, DA SILVA B, ARRIBAS J et al.: Significant sparing of peripheral lipoatrophy by HIV treatment with LPV/r + ZDV/3TC induction followed by LPV/r monotherapy compared to EFV + ZDV/3TC. Programs and Abstracts of XIV Conference of Retrovirus and Oportunistic Infections, Los Angeles, USA (25 – 28 February 2007):44 (Paper).
   Google Scholar
• GISOLF EH, ENTING RH, JURRIAANS S et al.: Cerebrospinal fluid HIV-RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine. AIDS (2000) 14:1583-1589.
   PubMed Web of Science ®Google Scholar
• GHOSN J, PEYTAVIN G, GALIMAN J et al.: Absence of HIV-1 shedding in the male genital tract after 1-year of lopinavir/ritonavir alone or in combination with combivir: a substudy of Monark trial. Programs and abstracts of 15th International HIV Drug Resistance Workshop, Sitges, Spain (13 – 17 June 2006):76 (Abstract).
   Google Scholar
• YEH RF, LETENDRE S, NOVAK IS et al.: Single agent therapy with lopinavir controls HIV-1 replication in central nervous system. Programs and abstracts of XIV Conference of Retrovirus and Oportunistic Infections, Los Angeles, USA (25 – 28 February 2007):381 (Paper).
   Google Scholar
• WHO: Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: toward universal access. World Health Organization, Geneva, Switzerland (2006).
   Google Scholar